A double-blind placebo-controlled trial of granulocyte colony- stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031)

Blood

Volumn 91, Issue 10, 1998, Pages 3607-3615

  Godwin, John E ^a   Kopecky, Kenneth J ^a   Head, David R ^a   Willman, Cheryl L ^a   Leith, Catherine P ^a   Hynes, Harry E ^a   Balcerzak, Stanley P ^a   Appelbaum, Frederick R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RAT; RISK BENEFIT ANALYSIS;

EID: 0032525248     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.10.3607.3607_3607_3615     Document Type: Article

References (33)

1. Johnson PR, Yin JA: Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk Lymphoma 16:51, 1994
2. Appelbaum FR, Fisher LD, Thomas ED, and the Seattle Marrow Transplant Team: Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: A five-year follow-up. Blood 72:179, 1988
3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
4. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Hermann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710, 1996
5. Mitus JA, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13:560, 1995
6. Taylor PRA, Reid MM, Stark AN, Brown N, Hamilton PJ, Proctor SJ: De novo acute myeloid leukemia in patients over 55-years-old: A population-based study of incidence, treatment and outcome. Leukemia 9:231, 1995
7. Peterson BA, Bloomfield CD: Treatment of acute non-lymphocytic leukemia in elderly patients: A prospective study of intensive chemotherapy. Cancer 40:647, 1977
8. Leoni F, Ciolli S, Giuliani G, Pascarella A, Caporale R, Salti F, Cervi L, Rossi Ferrini P: Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: Pharmacokinetic study and clinical results. Br J Haematol 90:169, 1995
9. Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ: Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial. Lancet 2:1236, 1986
10. Stein RS, Vogler VR, Winton EF, Cohen HJ, Raney MR, Bartolucci A: Therapy of acute myelogenous leukemia in patients over the age of 50: A randomized Southeastern Cancer Study Group trial. Leuk Res 14:895, 1990
11. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R: Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82, 1994
12. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457, 1995
13. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA for the Cancer and Leukemia Group B: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 22:1671, 1995
14. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332:1678, 1995
15. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive therapy for small cell lung cancer. Br J Cancer 56:809, 1987
16. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L: Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414, 1988
17. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high risk lymphoid malignancies. J Clin Oncol 12:1931, 1994
18. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A: A randomized, double-blind, placebo controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid luekemia. Blood 90:4710, 1997
19. Ohno R: G-CSF in the treatment of acute myeloid leukemia: Is it safe? Leuk Lymphoma 11:15, 1993 (suppl 2)
20. Cheson BD, Cassileth PS, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the National Cancer Institute-Sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia. J Clin Oncol 8:813, 1990
21. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103, 1975
22. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239, 1992
23. Cox DR: The Analysis of Binary Data. London, UK, Methuen, 1970
24. Kaplan EL, Meier P: Nonparametric estimate from incomplete observations. J Am Stat Assoc 53:457, 1958
25. Cox DR: Regresssion models and life tables. J R Stat Soc B 34:187, 1972
26. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400, 1993
27. Lin DY, Robins JM, Wei LJ: Comparing two failure time distributions in the presence of dependent censoring. Biometrika 83:381, 1996
28. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkbly distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323, 1997
29. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F: Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia: A randomized controlled study. N Eng J Med 323:871, 1990
30. Rowe J, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 11:328, 1997
31. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R: EORTC-LCG and HOVON. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer Cooperative Group (HOVON). Blood 90:2952, 1997
32. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675, 1996
33. Terpstra W, Löwenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11:315, 1997